Eagan Rt

668 total citations
29 papers, 565 citations indexed

About

Eagan Rt is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Eagan Rt has authored 29 papers receiving a total of 565 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Pulmonary and Respiratory Medicine, 18 papers in Oncology and 6 papers in Molecular Biology. Recurrent topics in Eagan Rt's work include Lung Cancer Research Studies (11 papers), Lung Cancer Treatments and Mutations (11 papers) and Neuroendocrine Tumor Research Advances (6 papers). Eagan Rt is often cited by papers focused on Lung Cancer Research Studies (11 papers), Lung Cancer Treatments and Mutations (11 papers) and Neuroendocrine Tumor Research Advances (6 papers). Eagan Rt collaborates with scholars based in United States. Eagan Rt's co-authors include Stephen Frytak, Kvols Lk, Carr Dt, Lee Re, Robert G. Hahn, Edmonson Jh, Jonah Rubin, O'Connell Mj, Joseph Rubin and Martin Scott and has published in prestigious journals such as PubMed and Munich Personal RePEc Archive (Ludwig Maximilian University of Munich).

In The Last Decade

Eagan Rt

28 papers receiving 490 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Eagan Rt United States	15	400	261	152	142	61	29	565
G Martz Switzerland	14	336 0.8×	122 0.5×	68 0.4×	93 0.7×	134 2.2×	36	535
E Longeval Belgium	10	294 0.7×	146 0.6×	112 0.7×	115 0.8×	66 1.1×	17	465
Hansen Hh Denmark	12	351 0.9×	247 0.9×	186 1.2×	142 1.0×	13 0.2×	35	539
J. Michel Belgium	15	662 1.7×	504 1.9×	201 1.3×	217 1.5×	66 1.1×	24	903
M Fukushima Japan	9	341 0.9×	238 0.9×	40 0.3×	159 1.1×	49 0.8×	37	639
Melissa Dinolfo United States	5	214 0.5×	159 0.6×	82 0.5×	106 0.7×	33 0.5×	7	363
Denise McLain United States	14	288 0.7×	223 0.9×	28 0.2×	240 1.7×	105 1.7×	32	690
Frédéric Vallot Belgium	7	359 0.9×	268 1.0×	62 0.4×	251 1.8×	109 1.8×	18	613
D. P. Ryan United States	13	241 0.6×	180 0.7×	44 0.3×	94 0.7×	83 1.4×	31	510
Comis Rl United States	6	190 0.5×	60 0.2×	57 0.4×	151 1.1×	15 0.2×	11	337

Countries citing papers authored by Eagan Rt

Since Specialization

Citations

This map shows the geographic impact of Eagan Rt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eagan Rt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eagan Rt more than expected).

Fields of papers citing papers by Eagan Rt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eagan Rt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eagan Rt. The network helps show where Eagan Rt may publish in the future.

Co-authorship network of co-authors of Eagan Rt

This figure shows the co-authorship network connecting the top 25 collaborators of Eagan Rt. A scholar is included among the top collaborators of Eagan Rt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eagan Rt. Eagan Rt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Frytak, Stephen, et al.. (1984). Phase I study of diaziquone.. PubMed. 68(7-8). 975–8. 4 indexed citations

Frytak, Stephen, et al.. (1984). Phase II study of diaziquone in patients with advanced carcinoma of the lung.. PubMed. 68(9). 1193–4. 1 indexed citations

Klášterský, Jean, et al.. (1983). Complications of treatment of small cell carcinoma of the lung.. PubMed. 67(1). 21–6. 21 indexed citations

Rt, Eagan, et al.. (1982). Evaluation of an intermittent schedule of mitolactol in advanced non-small cell lung cancer.. PubMed. 65(11-12). 1099–1101. 4 indexed citations

Rt, Eagan, et al.. (1982). Combination carmustine (BCNU) and dianhydrogalactitol in the treatment of primary brain tumors recurring after irradiation.. PubMed. 66(8). 1647–9. 16 indexed citations

Rt, Eagan, et al.. (1981). Thoracic radiation therapy and Adriamycin/cisplatin-containing chemotherapy for locally advanced non-small-cell lung cancer.. PubMed. 4(4). 381–8. 24 indexed citations

Rt, Eagan, et al.. (1981). Cyclophosphamide and VP-16-213 with or without cisplatin in squamous cell and small cell lung cancers.. PubMed. 65(5-6). 453–8. 10 indexed citations

Rt, Eagan, et al.. (1981). Early clinical trial of a 1-day intermittent schedule for pentamethylmelamine.. PubMed. 64(8-9). 993–5. 6 indexed citations

Rt, Eagan, et al.. (1981). Evaluation of VP-16-213, cyclophosphamide, doxorubicin, and cisplatin (V-CAP) in advanced large cell lung cancer.. PubMed. 65(7-8). 715–7. 7 indexed citations

10.

Rt, Eagan, et al.. (1981). A case for preplanned thoracic and prophylactic whole brain radiation therapy in limited small-cell lung cancer.. PubMed. 4(3). 261–6. 50 indexed citations

11.

Rt, Eagan, et al.. (1981). Phase II study of the combination of dianhydrogalactitol, doxorubicin, and cisplatin (DAP) in patients with advanced squamous cell lung cancer.. PubMed. 65(5-6). 517–9. 5 indexed citations

12.

Jh, Edmonson, Stephen Frytak, Louis Letendre, Kvols Lk, & Eagan Rt. (1980). Phase II evaluation of dianhydrogalactitol in advanced head and neck carcinomas.. PubMed. 63(11-12). 2081–3.

13.

Rt, Eagan, et al.. (1978). VP-16-213 chemotherapy for advanced squamous cell carcinoma and adenocarcinoma of the lung.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 62(5). 843–4. 42 indexed citations

14.

Rt, Eagan, et al.. (1978). cis-Dichlorodiammineplatinum(II) alone followed by adriamycin plus cyclophosphamide at progression versus cis-dichlorodiammineplatinum(II), adriamycin, and cyclophosphamide in combination for adenocarcinoma of the lung.. PubMed. 62(8). 1207–10. 48 indexed citations

15.

Rt, Eagan, et al.. (1977). Platinum-based polychemotherapy versus dianhydrogalactitol in advanced non-small cell lung cancer.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 61(7). 1339–45. 79 indexed citations

16.

Rt, Eagan, et al.. (1977). Cyclophosphamide, adriamycin, and DTIC polychemotherapy in advanced small cell lung cancer.. PubMed. 61(3). 481–3. 4 indexed citations

17.

Rt, Eagan, et al.. (1976). Phase II evaluation of VP-16-213 (NSC-141540) and cytembena (NSC-104801) in patients with advanced breast cancer.. PubMed. 60(5). 633–5. 22 indexed citations

18.

Rt, Eagan, et al.. (1976). ICRF-159 versus polychemotherapy in non-small cell lung cancer.. PubMed. 60(7). 947–8. 15 indexed citations

19.

Rt, Eagan, Carr Dt, Stephen Frytak, Jonah Rubin, & Lee Re. (1976). VP-16-213 versus polychemotherapy in patients with advanced small cell lung cancer.. PubMed. 60(7). 949–51. 41 indexed citations

20.

Rt, Eagan, et al.. (1974). Controlled evaluation of adriamycin (NSC-123127) in patients with disseminated breast cancer.. PubMed. 58(6). 877–82. 54 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact